Finally, Chadwick and colleagues demonstrated that MR antagonism by spironolactone was able to downregulate the Ankrd1 transcript in a Duchenne muscular dystrophy (DMD) mouse model, thus identifying Ankrd1 as a novel MR gene target [22]. This evidence concerns the gene NR3C2 and Duchenne muscular dystrophy.